Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs

Published:2019-08 Issue:8 Volume:123 Page:721-727
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Vokinger Kerstin Noëlle,Kesselheim Aaron S.

Funder

Laura and John Arnold Foundation

Harvard Program in Therapeutic Science and the Engelberg Foundation

Swiss National Foundation

the Swiss Cancer League

Publisher

Elsevier BV

Subject

Health Policy

Reference52 articles.

1. Do important drugs reach the market sooner?;Dranove;The RAND Journal of Economics,1994

2. Trends in utilization of FDA expedited drug development and approval programs, 1987–2014: cohort study;Kesselheim;BMJ,2015

3. Expedited programs for serious conditions: an update on breakthrough therapy designation;Kwok;Clinical Therapeutics,2015

4. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study;Mostaghim;BMJ,2017

5. Regulatory watch: characterizing the US FDA’s approach to promoting transformative innovation;Downing;Nature Reviews Drug Discovery,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval;Journal of Clinical Epidemiology;2024-10

2. Strength of Statistical Evidence for the Efficacy of Cancer Drugs: A Bayesian Re-Analysis of Trials Supporting FDA Approval;2023-06-30

3. Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018;Health Policy;2020-03

4. New drug approvals in oncology;Nature Reviews Clinical Oncology;2020-02-04

5. Access to Cancer Precision Medicines in Switzerland: A Comparative Analysis (USA and EU) and Health Policy Implications;Public Health Genomics;2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3